September 2016. After several months of hard work and dedication, we are thrilled to officially announce the launch of our new website! We invite you to visit us at www.genoskin.com We have built our new website with you in mind. The streamlined user interface provides a more interactive experience, allowing our colleagues, partners, clients and prospects to easily find the information
The NETVA (New Technology Venture Accelerator) program consists in a preparation and exposure to high-tech US markets for young innovative French companies. It is run by the Office for Science & Technology of the Embassy of France in the United States in three locations: Boston, San Francisco and Washington, DC. Each year, 15 French startups are selected though a national competition
NativeSkin® successfully treated with UVB after shipment from France to Australia May 2016. Dr. Ziman’s lab. (Edith Cowan University, Perth, Western Australia) reports the successful use of NativeSkin models, shipped from France to Australia, to study skin damages induced by UVB and heat. Researchers analyzed the consequences of UVB and/or heat treatments by co-immunofluorescence staining perform on NativeSkin skin models-fixed tissue, as shown in the
Genoskin launches new OncoSkin® skin cancer model at Meet2Win Genoskin has developed a new skin cancer model for the in vitro study of melanoma. Patients who suffer from this highly dangerous type of skin cancer currently have limited therapeutic options when the cancer reaches metastasis. The OncoSkin® skin cancer model now enables in vitro studies on live melanoma spheroids implanted
NativeSkin®, a novel skin explant model for skin delivery assessment The Genoskin team is proud to announce that Oriflame Cosmetics published an article in the March 2015 edition of Cosmetics & Toiletries under the title “A Novel Skin Explant Model For Skin Delivery Assessment”. The work presented in this article was conducted by Oriflame’s cosmetics experts in their facility in Stockholm. Genoskin has